

**Contact:**  
Bryan Murphy  
LaVoie Group  
(978) 745-4200 X 105  
[bmurphy@lavoiegroup.com](mailto:bmurphy@lavoiegroup.com)



**FOR IMMEDIATE RELEASE:**

**EYEGATE PHARMA TO PRESENT AT  
2007 BIO INTERNATIONAL CONVENTION AND ARVO**

**Waltham, MA – April 24, 2007** – EyeGate Pharma, a privately-held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced presentations at the 2007 BIO International Convention and The Association for Research in Vision and Ophthalmology's 2007 Annual Meeting (ARVO).

Stephen From, President and Chief Executive Officer, will present at the BIO Business Forum during the 2007 BIO International Convention (May 6-9, 2007) at the Boston Convention and Exhibition Center in Boston, MA. His presentation will take place on Tuesday, May 8 at 2:30 PM in room B. For more information about the 2007 BIO International Convention please visit [www.bio2007.org](http://www.bio2007.org). Mr. From will be available for one-on-one meetings during both the BIO Convention and ARVO.

Pierre Roy, et. al., a consultant to EyeGate and the company's former Chief Technical Officer, will make a poster presentation at ARVO 2007 (May 6-10, 2007) in Ft. Lauderdale, FL. Mr. Roy's poster presentation, titled, ***Ocular Tolerability of Iontophoresis in Rabbits*** (Program 5800 / Poster B337), will take place on May 10 from 10:45 AM to 12:30 PM in Hall B/C. For more information about ARVO 2007 please visit [www.arvo.org](http://www.arvo.org).

**About EyeGate Pharma**

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies using the EyeGate® II Delivery System are planned for 2008. For more information please visit [www.eyegatepharma.com](http://www.eyegatepharma.com).

# # #